GlassScriptPhysician profile
Mandy S Harting
NPI 1437324480
$7,471.53
in general payments reported to CMS, 2019-2025
25 companies · $2,119 in 2025
The $2,119 reported for 2025 was more than what 89% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $225 · 2021: $126 · 2022: $671 · 2023: $1,354 · 2024: $1,979 · 2025: $2,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,451.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,554.05 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,519.05 | 2019-2025 | |
| Lilly USA, LLC | $730.39 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $650.62 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $608.21 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $587.87 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $442.88 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $270.22 | 2019-2025 | |
| Ucb, INC. | $194.19 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $165.66 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.82 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Celgene Corporation | $130.31 | 2019 | |
| Allergan, INC. | $111.58 | 2021 | |
| Leo Pharma INC. | $74.17 | 2019-2025 | Anzupgo |
| Fresenius Kabi USA, LLC | $57.17 | 2023-2024 | Idacio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $49.03 | 2019 | |
| Almirall LLC | $36.21 | 2019 | |
| Krystal Biotech INC | $21.36 | 2025 | Vyjuvek |
| Dermavant Sciences, INC. | $18.73 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.60 | 2023 | Cyltezo |
| Teva Pharmaceuticals USA, INC. | $15.02 | 2024 | Simlandi |
| Verrica Pharmaceuticals INC. | $14.38 | 2025 | Ycanth |
| Botanix Sb INC | $14.29 | 2025 | Sofdra |
| Dermira, INC. | $13.71 | 2019 | |
| Biofrontera INC. | $9.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Harting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.